Literature DB >> 21666151

The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda.

David Bishai1, Benjamin Johns, Divya Nair, Juliet Nabyonga-Orem, Braka Fiona-Makmot, Emily Simons, Alya Dabbagh.   

Abstract

Supplemental Immunization Activities (SIAs) have become an important adjunct to measles control efforts in countries that endeavor to achieve higher levels of population immunity than can be achieved in a growing routine immunization system. Because SIAs are often supported with funds that have alternative uses, decision makers need to know how cost-effective they are compared with other options. This study integrated a dynamic stochastic model of measles transmission in Uganda (2010-2050) with a cost model to compare a strategy of maintaining Uganda's current (2008) levels of the first dose of routine measles-containing vaccine (MCV1) coverage at 68% with SIAs with a strategy using the same levels of MCV1 coverage without SIAs. The stochastic model was fitted with parameters drawn from district-level measles case reports from Uganda, and the cost model was fitted to administrative data from the Ugandan Expanded Program on Immunization and from the literature. A discount rate of 0.03, time horizon of 2010-2050, and a societal perspective on costs were assumed. Costs expressed in US dollars (2010) included vaccination costs, disease treatment costs including lost productivity of mothers, as well as costs of outbreaks and surveillance. The model estimated that adding on triennial SIAs that covered 95% of children aged 12-59 months to a system that achieved routine coverage rates of 68% would have an incremental cost-effectiveness ratio (ICER) of $1.50 ($US 2010) per disability-adjusted life year averted. The ICER was somewhat higher if the discount rate was set at either 0 or 0.06. The addition of SIAs was found to make outbreaks less frequent and lower in magnitude. The benefit was reduced if routine coverage rates were higher. This cost-effectiveness ratio compares favorably to that of other commonly accepted public health interventions in sub-Saharan Africa.
© The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21666151      PMCID: PMC3690572          DOI: 10.1093/infdis/jir131

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Measles antibody prevalence in diverse populations.

Authors:  F L BLACK
Journal:  Am J Dis Child       Date:  1962-03

Review 2.  Estimates of measles case fatality ratios: a comprehensive review of community-based studies.

Authors:  Lara J Wolfson; Rebecca F Grais; Francisco J Luquero; Maureen E Birmingham; Peter M Strebel
Journal:  Int J Epidemiol       Date:  2009-02       Impact factor: 7.196

3.  Measles in Kenyan children.

Authors:  C O'Donovan
Journal:  East Afr Med J       Date:  1971-10

4.  Cost-effectiveness of supplementary immunization for measles in India.

Authors:  Mayank Dabral
Journal:  Indian Pediatr       Date:  2009-05-20       Impact factor: 1.411

5.  Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis.

Authors:  J F Modlin; J T Jabbour; J J Witte; N A Halsey
Journal:  Pediatrics       Date:  1977-04       Impact factor: 7.124

  5 in total
  17 in total

1.  Effect of measles prevalence and vaccination coverage on other disease burden: evidence of measles immune amnesia in 46 African countries.

Authors:  Ryoko Sato; Masahiko Haraguchi
Journal:  Hum Vaccin Immunother       Date:  2021-12-29       Impact factor: 3.452

2.  Measles vaccination using a microneedle patch.

Authors:  Chris Edens; Marcus L Collins; Jessica Ayers; Paul A Rota; Mark R Prausnitz
Journal:  Vaccine       Date:  2012-10-05       Impact factor: 3.641

3.  Vaccination and all-cause child mortality from 1985 to 2011: global evidence from the Demographic and Health Surveys.

Authors:  Mark E McGovern; David Canning
Journal:  Am J Epidemiol       Date:  2015-10-08       Impact factor: 4.897

4.  Age-specific mixing generates transient outbreak risk following critical-level vaccination.

Authors:  S Bhattacharyya; M J Ferrari
Journal:  Epidemiol Infect       Date:  2016-09-28       Impact factor: 4.434

5.  The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study.

Authors:  Kenzo Takahashi; Yasushi Ohkusa; Jong-Young Kim
Journal:  BMC Health Serv Res       Date:  2011-10-07       Impact factor: 2.655

6.  Updating the evidence base on the operational costs of supplementary immunization activities for current and future accelerated disease control, elimination and eradication efforts.

Authors:  Gian Gandhi; Patrick Lydon
Journal:  BMC Public Health       Date:  2014-01-22       Impact factor: 3.295

Review 7.  Mathematical modeling of infectious disease dynamics.

Authors:  Constantinos I Siettos; Lucia Russo
Journal:  Virulence       Date:  2013-04-03       Impact factor: 5.882

8.  Supplementary immunization activities (SIAs) in South Africa: comprehensive economic evaluation of an integrated child health delivery platform.

Authors:  Stéphane Verguet; Waasila Jassat; Melanie Y Bertram; Stephen M Tollman; Christopher J L Murray; Dean T Jamison; Karen J Hofman
Journal:  Glob Health Action       Date:  2013-03-01       Impact factor: 2.640

9.  Cost-effectiveness analysis of routine immunization and supplementary immunization activity for measles in a health district of Benin.

Authors:  Landry Kaucley; Pierre Levy
Journal:  Cost Eff Resour Alloc       Date:  2015-08-20

10.  Modeling the Impact of Alternative Immunization Strategies: Using Matrices as Memory Lanes.

Authors:  Wladimir J Alonso; Maia A Rabaa; Ricardo Giglio; Mark A Miller; Cynthia Schuck-Paim
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.